Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q1 2019 · 10-Q
Revenue$10.69M$10.69M−3.4% vs Q1 2018 Net Income-$1.86M-$1.86MN/M vs Q1 2018 EPS Diluted-$1.09-$1.09N/M vs Q1 2018 Gross Profit$2,139,964−8.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Operating Cash Flow-$984,134N/M Margins · derivedGross margin20.0%−1.2 pt vs Q1 2018
Operating margin-12.1%+0.2 pt vs Q1 2018
Net margin-17.4%−3.2 pt vs Q1 2018
ended Mar 31, 2019 · filed May 14, 2019 · 44 d after period end